NewSquare Capital LLC Cuts Stock Position in Sanofi (NASDAQ:SNY)

NewSquare Capital LLC decreased its holdings in Sanofi (NASDAQ:SNY) by 0.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 111,100 shares of the company’s stock after selling 940 shares during the quarter. NewSquare Capital LLC’s holdings in Sanofi were worth $5,293,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Synergy Asset Management LLC purchased a new position in Sanofi in the 4th quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Sierra Ocean LLC acquired a new position in Sanofi during the 4th quarter worth $44,000. Finally, Versant Capital Management Inc purchased a new stake in Sanofi during the 4th quarter worth about $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Trading Up 2.1 %

SNY opened at $57.70 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a market cap of $146.43 billion, a P/E ratio of 23.17, a PEG ratio of 1.01 and a beta of 0.57. The business’s 50-day simple moving average is $52.00 and its 200-day simple moving average is $52.64.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.